Clinical trial
Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell…
NCT00034697 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00034697 |
|---|---|
| Title | Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143) |
| Official title | A Phase II Study of Temozolomide (SCH 52365) in Subjects With Brain Metastasis From Non-Small-Cell Lung Cancer |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastases, Neoplasm, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms |
| Intervention type | Drug |
| Interventions | temozolomide |
| Enrollment | 24 |
| Start date | Jun 28, 2001 |
| Primary completion | Jan 30, 2003 |
| Completion | Jan 30, 2003 |
| First posted | May 2, 2002 |
| Last update posted | May 23, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: